Abstract

RadNet will release fiscal second-quarter results on August 09, 2026 Post-Mkt; the preview below summarizes consensus forecasts, last quarter’s performance, segment dynamics, and institutional views for the period ending June 2026.

Market Forecast

Consensus for the current quarter points to revenue of 607.87 million US dollars, EBIT of 34.95 million US dollars, and EPS of 0.19 with year-over-year changes of 24.31%, -8.85%, and 20.36%, respectively; the projected mix implies stabilization in operating profitability but modest pressure on operating income compared with last year. Forecast commentary suggests core imaging services remain the centerpiece, while AI-enabled diagnostics and value-based arrangements are expected to support pricing and volume, with limited margin headwinds from wage and radiologist costs. The core services business is anticipated to expand on higher scan volumes and new center openings, while the most promising growth engine is services-related revenue, projected to account for the majority of revenue this quarter; management emphasis remains on scaling service fee revenue with improving yield per procedure.

Last Quarter Review

RadNet posted revenue of 575.63 million US dollars, a gross profit margin of 4.96%, GAAP net loss attributable to shareholders of 33.47 million US dollars, and a net profit margin of -5.81%; adjusted EPS was -0.28, up 20.00% year over year. Quarter-on-quarter change in GAAP net income was -5,505.70%, reflecting a swing driven by expense timing and investment in growth initiatives. A notable highlight was revenue growth of 22.11% year over year despite negative GAAP earnings. The main business comprised service fee revenue of 545.22 million US dollars and amortized arrangement revenue of 30.41 million US dollars, indicating services accounted for 94.72% of the mix.

Current Quarter Outlook

Main business: imaging services utilization and pricing

The primary driver this quarter is expected to be imaging services, where forecast revenue implies continued high-teens to mid-20s growth on the back of elevated procedure volumes and favorable modality mix. Utilization trends across MRI and CT remain resilient in outpatient settings, helping offset seasonal softness in certain geographies. Unit economics should benefit from procedural mix and selective contract repricing, though wage inflation and radiologist staffing expenses may limit flow-through to operating margins. Given the estimated revenue increase of 24.31%, we expect management to focus on throughput, scheduling efficiency, and payer authorization cycle times to protect gross margin from labor and consumable cost pressures. Even with EBIT forecast to decline year over year, the spread between revenue growth and EBIT change suggests heavier operating investments or compensation accruals, which could reverse as integration synergies and efficiency efforts mature into the second half of the year. Watch commentary on same-center volume, price per exam, and center openings or closures to gauge the durability of revenue momentum. The last reported mix shows that service fee revenue represented 545.22 million US dollars out of total revenue, underscoring the concentration in core imaging services. Any expansion in advanced modalities, including 3T MRI and PET/CT, can lift yield per procedure, which would help stabilize gross margin even if staffing expenses remain elevated.

Most promising growth engine: services-led expansion

Services remain the largest and fastest-scaling contributor, with last quarter services at 545.22 million US dollars and sustaining a high share of total revenue. In the current quarter, the revenue forecast of 607.87 million US dollars implicitly assumes services continue to advance as the main pillar. Growth levers include higher scan volumes from network densification, payer steerage to outpatient centers, and improved scheduling density. The key watch items are authorization friction and payer mix. If commercial volumes hold and Medicare Advantage headwinds are contained, revenue realization per procedure should remain healthy. The EBIT outlook, down 8.85% year over year, indicates continued spending on growth capacity and technology, which could have a delayed EPS benefit but supports share gains in local markets. An inflection toward better operating leverage may emerge if volumes surpass staffing and facility cost growth. The business is also likely to benefit from the maturation of prior investments, including center upgrades and modality expansion. If ramping sites reach breakeven throughput targets in the quarter, margin pressure should ease, narrowing the gap between revenue growth and EBIT trends.

Key stock price driver: profitability trajectory versus investment cadence

The market is set to focus on whether margin performance inflects alongside robust revenue growth. With EPS projected at 0.19 and up 20.36% year over year, investors will look for confirmation that the path to earnings expansion is intact despite EBIT’s projected decline. Positive surprises could come from lower-than-expected overtime and locum tenens costs, tighter operating expense control, and revenue per exam outperformance. Conversely, risk factors include prolonged wage inflation, lingering radiologist capacity constraints, and slower-than-anticipated ramp at newly opened or acquired centers. Any commentary pointing to higher contract labor or technology amortization could weigh on margin expectations. The balance between growth investments and near-term profitability will likely dominate the stock reaction, making guidance on second-half operating leverage and cash conversion a central focus. Management’s discussion of payor dynamics and authorization processes will be critical for volume visibility into the next quarter. Evidence of reduced denials and faster scheduling conversion can support continued double-digit revenue growth while relieving cost pressure, providing a clearer bridge to improved EBIT and EPS cadence.

Analyst Opinions

Institutional commentary in recent months has leaned constructive on RadNet’s revenue trajectory and volume growth normalization, with the majority of preview notes characterizing the setup as favorable for top-line acceleration while acknowledging near-term EBIT pressure. Several well-followed sell-side firms highlight the company’s strong footprint in outpatient imaging and improving throughput as reasons to expect revenue outperformance versus consensus, while urging vigilance on staffing costs and authorization bottlenecks. The prevailing view is bullish, emphasizing sustained demand in advanced imaging modalities and operational execution as catalysts for the quarter. Analysts anticipate that any EBIT softness is transitory and tied to planned investments, with an expectation that operating leverage improves into the second half as new centers scale. The constructive stance rests on ongoing double-digit revenue growth, improving EPS, and healthy appointment pipelines, which, if validated by management commentary on August 09, 2026, could reinforce the positive bias in estimates for the remainder of the year.